Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA...

por Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik
Publicado 2021

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry...

por Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur
Publicado 2021